

DOCKET NO. 100051.11211
PATENT

SERIAL NO. 10/611,533
FILED: June 30, 2003

AMENDMENTS TO THE CLAIMS:

Please amend claims 41, 42, 44, 45, 47, and 48 and add new claims 49-61 as follows.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously presented) An in vitro method of screening an individual for metastatic colorectal cancer cells or metastatic stomach cancer cells or metastatic esophageal cancer cells comprising the step of examining a sample of extraintestinal tissue and/or body fluids from an individual to determine whether CDX1 is being expressed by cells in said sample wherein expression of said CDX1 indicates a possibility of metastatic colorectal cancer cells or metastatic stomach cancer cells or metastatic esophageal cancer cells in said sample.
2. (Original) The method of claim 1 wherein expression of said CDX1 by said cells is determined by detecting the presence of CDX1 gene transcription product.
3. (Original) The method of claim 1 wherein expression of said CDX1 by said cells is determined by polymerase chain reaction wherein said sample is contacted with primers that selectively amplify CDX1 gene transcript or cDNA generated therefrom.
- 4-7. (Canceled)
8. (Original) The method of claim 1 wherein said sample is a lymph node sample.
9. (Original) The method of claim 1 wherein the individual has previously been diagnosed with having colorectal, stomach or esophageal cancer.

DOCKET NO. 100051.11211
PATENT

SERIAL NO. 10/611,533
FILED: June 30, 2003

10. (Original) The method of claim 1 wherein the individual has previously been diagnosed with and treated for colorectal, stomach or esophageal cancer

11. (Original) An in vitro method of screening an individual for metastatic colorectal cancer or metastatic stomach cancer or metastatic esophageal cancer comprising the step of examining a sample of extraintestinal tissue and/or body fluids from an individual to determine whether CDX1 gene transcription or translation product is present in said sample wherein the presence of CDX1 gene transcription or translation product in said sample indicates that the individual may have metastatic colorectal cancer or metastatic stomach cancer or metastatic esophageal cancer.

12. (Original) The method of claim 11 comprising the steps of examining a sample of extraintestinal tissue and/or body fluids from an individual to determine whether CDX1 gene transcription product is present in said sample.

13. (Original) The method of claim 12 wherein the presence of CDX1 gene transcription product is determined by polymerase chain reaction wherein said sample is contacted with primers that selectively amplify CDX1 gene transcript or cDNA generated therefrom.

14-18. (Canceled)

19. (Original) The method of claim 11 wherein the individual has previously been diagnosed with having colorectal, stomach or esophageal cancer.

20. (Original) The method of claim 11 wherein the individual has previously been diagnosed with and treated for colorectal, stomach or esophageal cancer

21-28. (Canceled)

29. (Previously presented) A method of diagnosing an individual who has metastatic esophageal cancer in an individual who has previously been diagnosed with having esophageal cancer comprising the step of examining a body fluid or lymph node sample to detect the presence of CDX1 transcript or translation product wherein the presence of CDX1 transcript or translation product in said sample indicates that the individual has metastatic esophageal cancer.

30. (Previously presented) The method of claim 29 comprising the step of examining said sample to determine whether CDX1 gene transcription product is present in said sample.

31. (Original) The method of claim 30 wherein the presence of CDX1 gene transcription product is determined by polymerase chain reaction wherein said sample is contacted with primers that selectively amplify CDX1 gene transcript or cDNA generated therefrom.

32-38. (Canceled).

39. (Previously presented) The method of claim 29 wherein said sample is a lymph node sample.

40. (Previously presented) The method of claim 1 wherein said CDX1 is encoded by SEQ ID NO:1.

41. (Currently Amended) The method of claim 1 wherein said CDX1 is encoded by GenBank Accession No. U51095 SEQ ID NO: 3.

DOCKET NO. 100051.11211
PATENT

SERIAL NO. 10/611,533
FILED: June 30, 2003

42. (Currently Amended) The method of claim 1 wherein said CDX1 is encoded by
~~GenBank Accession No. U15212 SEQ ID NO: 4.~~

43. (Previously presented) The method of claim 11 wherein said CDX1 is encoded by SEQ ID NO:1.

44. (Currently Amended) The method of claim 11 wherein said CDX1 is encoded by
~~GenBank Accession No. U51095 SEQ ID NO: 3.~~

45. (Currently Amended) The method of claim 11 wherein said CDX1 is encoded by
~~GenBank Accession No. U15212 SEQ ID NO: 4.~~

46. (Previously presented) The method of claim 29 wherein said CDX1 is encoded by SEQ ID NO:1.

47. (Currently Amended) The method of claim 29 wherein said CDX1 is encoded by
~~GenBank Accession No. U51095 SEQ ID NO: 3.~~

48. (Currently Amended) The method of claim 29 wherein said CDX1 is encoded by
~~GenBank Accession No. U15212 SEQ ID NO: 4.~~

49. (New) A method of diagnosing an individual who has metastatic colorectal cancer in an individual who has previously been diagnosed with having colorectal cancer comprising the step of examining a body fluid or extraintestinal sample to detect the presence of CDX1 transcript or translation product wherein the presence of CDX1 transcript or translation product in said sample indicates that the individual has metastatic colorectal cancer.

DOCKET NO. 100051.11211
PATENT

SERIAL NO. 10/611,533
FILED: June 30, 2003

50. (New) The method of claim 49, wherein said sample is a lymph node sample.
51. (New) The method of claim 49, wherein said wherein said CDX1 is encoded by SEQ ID NOS: 1, 3, or 4.
52. (New) The method of claim 49, wherein said wherein said CDX1 is encoded by SEQ ID NOS: 1.
53. (New) The method of claim 49 wherein expression of said CDX1 by a cell in said sample is determined by detecting the presence of CDX1 gene transcription product.
54. (New) The method of claim 49 wherein expression of said CDX1 is determined by polymerase chain reaction wherein said sample is contacted with primers that selectively amplify CDX1 gene transcript or cDNA generated therefrom.
55. (New) An in vitro method of screening an individual for metastatic colorectal cancer cells comprising the step of examining a sample of extraintestinal tissue and/or body fluids from an individual to determine whether CDX1 is being expressed by cells in said sample wherein expression of said CDX1 indicates a possibility of metastatic colorectal cancer cells in said sample.
56. (New) The method of claim 55, wherein said individual has been previously diagnosed with colorectal cancer.
57. (New) The method of claim 55 wherein said sample is a lymph node sample.

DOCKET NO. 100051.11211
PATENT

SERIAL NO. 10/611,533
FILED: June 30, 2003

58. (New) The method of claim 55, wherein said wherein said CDX1 is encoded by SEQ ID NOS: 1, 3, or 4.

59. (New) The method of claim 55, wherein said wherein said CDX1 is encoded by SEQ ID NOS: 1.

60. (New) The method of claim 55 wherein expression of said CDX1 by said cells is determined by detecting the presence of CDX1 gene transcription product.

61. (New) The method of claim 55 wherein expression of said CDX1 by said cells is determined by polymerase chain reaction wherein said sample is contacted with primers that selectively amplify CDX1 gene transcript or cDNA generated therefrom.